ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on September 3, 2024. The company, incorporated in Delaware and headquartered in Weston, FL, is preparing to potentially offer various forms of securities to the public. These securities may include common stock, preferred stock, debt securities, warrants, purchase contracts, units, and subscription rights. The registration statement includes a business combination agreement, forms of indenture, and other legal documents. The company's financial statements for the year ended December 31, 2023, have been audited by Marcum LLP, while Ernst & Young LLP audited the financial statements for the period ending December 31, 2022. The registration allows ZyVersa Therapeutics to offer securities in one or more separate series through...Show More

ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on September 3, 2024. The company, incorporated in Delaware and headquartered in Weston, FL, is preparing to potentially offer various forms of securities to the public. These securities may include common stock, preferred stock, debt securities, warrants, purchase contracts, units, and subscription rights. The registration statement includes a business combination agreement, forms of indenture, and other legal documents. The company's financial statements for the year ended December 31, 2023, have been audited by Marcum LLP, while Ernst & Young LLP audited the financial statements for the period ending December 31, 2022. The registration allows ZyVersa Therapeutics to offer securities in one or more separate series through underwritten public offerings, direct sales, or other methods. The specific terms and distribution plan for any offered securities will be detailed in future prospectus supplements. ZyVersa's directors and officers are indemnified against certain liabilities, and the company maintains liability insurance for them. The registration statement's effectiveness is subject to the SEC's review, and the company will undertake to file necessary amendments and documents as required by the SEC.